Jim Cramer flags Onto Innovation downside, backs select beaten-down stocks in lightning round
Television stock picks remain closely watched by retail traders as investors weigh rate pressure and valuation risks across growth shares. In a rapid-fire "Mad Money" segment, Jim Cramer says Onto Innovation is likely to fall further while offering mixed views on names including UiPath, Affirm and NIO.
Highlights
- Jim Cramer warns Onto Innovation stock remains overvalued given Fed's inflation fight, expecting further downside despite company strength.
- He endorses Karman Holdings for its cheap valuation, while rejecting UiPath due to lack of catalysts despite attractive pricing.
- Cramer advises cautious, gradual buying in Affirm citing confidence in CEO Max Levchin, but highlights risk from conflicting with Fed policy.
Rapid-fire calls across tech and consumer stocks
As reported by CNBC, Cramer uses the latest lightning round to sort through a range of stocks that he sees very differently based on valuation, catalysts and the interest-rate backdrop.On UiPath, he says the stock looks cheap but lacks a catalyst, leading him to reject it despite the lower price. He takes the opposite view on Karman Holdings, saying the shares are inexpensive enough for him to endorse them.
For Affirm, Cramer says investors are effectively pushing against Federal Reserve policy when buying the stock, but he still supports starting a position gradually. He points to confidence in CEO Max Levchin and suggests scaling in at lower price levels rather than buying all at once.
On Onto Innovation, Cramer says the company is solid but argues the stock is still too expensive for an environment in which the Fed is fighting inflation. That valuation concern leads him to conclude the shares are likely to move lower.
Rate pressure shapes risk appetite
Cramer's comments underline how monetary policy remains a key filter for stock selection, particularly for technology and other growth-oriented names where valuations are more sensitive to higher rates.He also strikes a cautious tone on NIO, warning that very low-priced stocks can still fall to zero and suggesting holders should be prepared to lose their investment. On Alnylam Pharmaceuticals, he calls the stock inexpensive but says he prefers exposure to Regeneron, Vertex and Amgen instead.
Previously, we examined UiPath bearish momentum as the stock traded below key moving averages after sliding to $11.34.